Lipocine (LPCN) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 4, 2025, at the company’s Salt Lake City office, with six proposals on the agenda, including director elections, auditor ratification, executive compensation, a reduction in authorized shares, and potential adjournment to solicit votes.

• Shareholders of record as of April 7, 2025, are eligible to vote, with one vote per share; a quorum requires one-third of outstanding shares.

• Proxy materials are primarily distributed via the Internet to conserve resources and reduce costs.

Voting matters and shareholder proposals

• Six directors are up for election to serve until the 2026 annual meeting.

• Ratification of Tanner LLC as the independent auditor for 2025 is proposed.

• Advisory approval of executive compensation (say-on-pay) is on the ballot.

• Proposal to amend the certificate of incorporation to reduce authorized common stock from 200,000,000 to 75,000,000 shares.

• Adjournment proposal allows the meeting to be postponed to solicit more votes if necessary.

Board of directors and corporate governance

• The board consists of six members, with a majority being independent; the chairman and lead independent director roles are separated from the CEO.

• Board committees include Audit and Compensation; there is no separate Nominating Committee, with all directors participating in nominations.

• The board emphasizes diversity, with a matrix showing gender and ethnic representation.

• Directors attended over 75% of meetings in 2024; a code of ethics and insider trading policy are in place.